Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

New England Journal of Medicine

Volumn 369, Issue 26, 2013, Pages 2492-2503

  De Zeeuw, Dick ^a   Akizawa, Tadao ^b   Audhya, Paul ^c   Bakris, George L ^d   Chin, Melanie ^c   Christ Schmidt, Heidi ^f   Goldsberry, Angie ^c   Houser, Mark ^e   Krauth, Melissa ^c   Lambers Heerspink, Hiddo J ^a   McMurray, John J ^g   Meyer, Colin J ^c   Parving, Hans Henrik ^h   Remuzzi, Giuseppe ⁱ   Toto, Robert D ^j   Vaziri, Nosratola D ^k   Wanner, Christoph ^l,n   Wittes, Janet ^f   Wrolstad, Danielle ^f   Chertow, Glenn M ^m   Toto, B ⁿ   McCullough, P ⁿ   Ivanovich, P ⁿ   Ketteler, M ⁿ   Lachin, J ⁿ   McGill, J ⁿ   Agarwal, R ⁿ   Anker, S ⁿ   Arenillas, J F ⁿ   Januzzi, J ⁿ   Jardine, A ⁿ   Kasner, S ⁿ   Kissela, B ⁿ   Kolansky, D ⁿ   Mann, J ⁿ   Thadhani, R ⁿ   Champion de Crespigny, P ⁿ   Chan, D T ⁿ   D'Almeida, E ⁿ   Fraser, I ⁿ   Gray, N ⁿ   Holt, S ⁿ   Irish, A ⁿ   Isbel, N ⁿ   Kerr, P ⁿ   Packham, D ⁿ   Phoon, R ⁿ   Pollock, C ⁿ   Roger, S ⁿ   Suranyi, M ⁿ   Walker, R ⁿ   Wittert, G ⁿ   Yue, D ⁿ   Balcke, P ⁿ   Prager, R ⁿ   Schernthaner, G ^n,n   Sunder Plassmann, G ⁿ   Jadoul, M ⁿ   Krzesinski, J M ⁿ   Peeters, P ⁿ   Van der Niepen, P ⁿ   Van Gaal, L ⁿ   Van Vlem, B ⁿ   Warling, X ⁿ   Chow, S ⁿ   Cournoyer, S ⁿ   Dumas, R ⁿ   Jolly, S ⁿ   Levin, A ⁿ   McMahon, A ⁿ   Mehta, H ⁿ   Ooi, T C ⁿ   Perkins, D ⁿ   Roy, L ⁿ   Sapir, D ⁿ   Tam, P ⁿ   Bartaskova, D ⁿ   Hemzsky, L ⁿ   Kubina, D ⁿ   Szabo, M ⁿ   Tesar, V ⁿ   Combe, C ⁿ   Faller, B ⁿ   Fauvel, J P ⁿ   Halimi, J M ⁿ   Hourmant, M ⁿ   Le Meur, Y ⁿ   Urena Torres, P ⁿ   Zaoui, P ⁿ   Al Sarraf, S ⁿ   Burst, V ⁿ   Degenhardt, S ⁿ   Kempe, H P ⁿ   Kleophas, W ⁿ   Kosch, C ⁿ   Krumme, B ⁿ   Kuhlmann, M ⁿ   Pistrosch, F ⁿ   Rambausek, M ⁿ   Schmidt Guertler, H ⁿ   Segiet, T ⁿ   Sommerer, C ⁿ   Vielhauer, V ⁿ   Beberashvili, I ⁿ   Benchetrit, S ⁿ   Herskovits, T ⁿ   Karnieli, E ⁿ   Levin Iaina, N ⁿ   Mosenzon, O ⁿ   Tsur, A ⁿ   van Dijk, D J ⁿ   Wainstein, J ⁿ   Yagil, Y ⁿ   Yerushalmi, Y ⁿ   Colussi, G ⁿ   Conte, G ⁿ   Di Luca, M ⁿ   Giovambatista, C ⁿ   Messa, P ⁿ   Pani, A ⁿ   Pisani, A ⁿ   Rapana, M R ⁿ   Ruggenenti, P ⁿ   Villa, G ⁿ   Zoccali, C ⁿ   Correa Rotter, R ⁿ   Diaz Escobedo, S L ⁿ   Garcia, P ⁿ   Gonzalez Galvez, G ⁿ   Obrador Vera, G T ⁿ   Rico, R ⁿ   Calero, F ⁿ   Cigarran, S ⁿ   de Alvaro, F ⁿ   de Francisco, A L ⁿ   Egido, J ⁿ   Fernandez, E ⁿ   Fernandez Vega, F ⁿ   Fort, J ⁿ   Galan Serrano, A ⁿ   Gorriz Teruel, J L ⁿ   Martinez, I ⁿ   Martinez Castelao, A ⁿ   Munar, M A ⁿ   Navarro, J ⁿ   Nieto, J ⁿ   Osuna, A ⁿ   Pascual, J ⁿ   Portoles, J ⁿ   Praga, M ⁿ   Valles M ⁿ   Fellstrom, B ⁿ   Frisenette Fich, C ⁿ   Hadimeri, H ⁿ   Stenvinkel, P ⁿ   Svensson, M ⁿ   Weiss, L ⁿ   Adamson, K ⁿ   Dornhorst, A ⁿ   El Kossi, M ⁿ   Gnudi, L ⁿ   Hendry, B ⁿ   Johnson, A ⁿ   Joseph, F ⁿ   Kalra, P ⁿ   Marshall, S ⁿ   Mikhail, A ⁿ   Myint, K S ⁿ   Soran, H ⁿ   Taal, M ⁿ   Zehnder, D ⁿ   Abbott, L ⁿ   Acharya, A ⁿ   Ahmed, Z ⁿ   Aiello, J ⁿ   Akom, M ⁿ   Ali, S ⁿ   Alzohaili, O ⁿ   Anderson, L ⁿ   Anderson, S ⁿ   Anger, M ⁿ   Appel, G ⁿ   Arakaki, R F ⁿ   Arif, A ⁿ   Assefi, A R ⁿ   Atray, N ⁿ   Awad, A ⁿ   Barranco, E ⁿ   Belledonne, M O ⁿ   Belo, D ⁿ   Bernardo, M ⁿ   Bernstein, R ⁿ   Bhalla, V ⁿ   Bhatia, D ⁿ   Black, R M ⁿ   Block, G ⁿ   Blondin, J ⁿ   Blumenthal, S S ⁿ   Bononi, P ⁿ   Brantley, R R ⁿ   Bresssler, P ⁿ   Broumand, V ⁿ   Brusco, O ⁿ   Buerkert, J ⁿ   Burgos Calderon, R ⁿ   Campbell, R ⁿ   Canas, G ⁿ   Cangiano, J ⁿ   Cherlin, R ⁿ   Chilakapati, V ⁿ   Comunale, R ⁿ   Coyne, D ⁿ   Crawford, P W ⁿ   Darwish, R ⁿ   Deeb, W ⁿ   Denker, P S ⁿ   Desai, S ⁿ   Desouza, C ⁿ   Diamond, S ⁿ   Dixon, B S ⁿ   Durham, J H ⁿ   Eisner, G ⁿ   Elder, J G ⁿ   El Shahawy, M ⁿ   Fadda, G ⁿ   Fitz Patrick, D ⁿ   Fonseca, V ⁿ   Fraser, N J ⁿ   Frei, G ⁿ   Fried, L ⁿ   Galindo Ramos, E ⁿ   Germain, M ⁿ   Ghantous, W ⁿ   Gilbert, J M ⁿ   Gillum, D ⁿ   Godwin, J ⁿ   Goel, A ⁿ   Goldfarb, DS ⁿ   Graf, R J ⁿ   Greenwood, T ⁿ   Guasch, A ⁿ   Hanna, A ⁿ   Harper, K ⁿ   Herman, T ⁿ   Hilton, T ⁿ   Hines, T ⁿ   Hoggard, J ⁿ   Hootkins, R ⁿ   Huseman, R ⁿ   Israelit, A ⁿ   Jamal, A ⁿ   Kant, K ⁿ   Kaptein, E ⁿ   Kathresal, A ⁿ   Kaupke, J ⁿ   Kaveh, K ⁿ   Kaye, W ⁿ   Keightley, G E ⁿ   Keith, K ⁿ   Khairullah, Q ⁿ   Kondle, V ⁿ   Kopyt, N ⁿ   Krishna, G ⁿ   Lawrence, M K ⁿ   LeBeau, M ⁿ   Leehey, D J ⁿ   Levine, M M ⁿ   Levinson, D ⁿ   Lew, S Q ⁿ   Lewis, D ⁿ   Linfert, D ⁿ   Liss, K ⁿ   Lund, R ⁿ   Madeleine, P ⁿ   Mahmood, K ⁿ   Martin, E R ⁿ   Martinez, C ⁿ   Mayeda, S O ⁿ   Mendez, R ⁿ   Middleton, J ⁿ   Molitch, M E ⁿ   Moncrief, J ⁿ   Moustafa, M ⁿ   Muoneke, R ⁿ   Murray, A V ⁿ   Murugan, T S ⁿ   Nammour, T M ⁿ   Nassar, G ⁿ   Navaneethan, S ⁿ   Newman, J ⁿ   Nossuli, A ⁿ   Nwakoby, I ⁿ   Osama, S ⁿ   Ouseph, R ⁿ   Parker, J ⁿ   Parnes, E ⁿ   Patel, N ⁿ   Pergola, P ⁿ   Perlman, A ⁿ   Perry, R G ⁿ   Petrillo, R ⁿ   Prabhakar, S ⁿ   Purighalla, R S ⁿ   Quesada Suarez, L ⁿ   Rabiei, A ⁿ   Raskin, P ⁿ   Rastogi, A ⁿ   Reisin, E ⁿ   Rekhi, A ⁿ   Rivera Colon, L ⁿ   Rizk, D ⁿ   Rodelas, R ⁿ   Roer, D ⁿ   Rosas, S ⁿ   Ross, D L ⁿ   Rovner, S ⁿ   Sackel, H ⁿ   Sader, S ⁿ   Santos, P ⁿ   Schmidt, R ⁿ   Shafik, S ⁿ   Shakeel, M ⁿ   Sharon, Z ⁿ   Silva, A L ⁿ   Silva, A ⁿ   Singh, B ⁿ   Smith, M ⁿ   Solomon, R ⁿ   Soman, S ⁿ   Spinowitz, B ⁿ   Sprague, S M ⁿ   Spry, L ⁿ   Stonesifer, L ⁿ   Streja, D ⁿ   Suchinda, P ⁿ   Sun, C ⁿ   Thakar, C V ⁿ   Trespalacios, F ⁿ   Tumlin, J A ⁿ   Van Buren, P ⁿ   Vernace, M ⁿ   Vicks, S ⁿ   Warren, M ⁿ   Weiss, D ⁿ   Welker, J ⁿ   Winston, J A ⁿ   Wombolt, D G ⁿ   Wood, M ⁿ   Wu, M ⁿ   Wynne, A ⁿ   Yu, H ⁿ   Zabaneh, R I ⁿ   more..

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Reata Pharmaceuticals   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e ABBVIE INC   (United States)

^f University of Iowa   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF WÜRZBURG   (Germany)

^m STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BARDOXOLONE METHYL; CREATININE; PLACEBO;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BACTEREMIA; BACTERIAL INFECTION; BLEEDING; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CONSCIOUSNESS DISORDER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; DRUG SAFETY; EDEMA; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; FUNGEMIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART FAILURE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY FAILURE; LOWER RESPIRATORY TRACT INFECTION; LUNG EDEMA; LUNG EMBOLISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTENSION; MULTICENTER STUDY; NAUSEA; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SEPSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY ALBUMIN TO CREATININE RATIO; URINARY TRACT INFECTION; URINE LEVEL; VIREMIA; VOMITING;

EID: 84890946148     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1306033     Document Type: Article

References (22)

1. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877-84.
2. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
3. Parving HH, Andersen AR, Smidt UM, Svendsen PA. Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
4. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
6. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
7. Heerspink HJ, de Zeeuw D. The kidney in type 2 diabetes therapy. Rev Diabet Stud 2011;8:392-402.
8. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-32.
9. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
10. Packham DK, Wolfe R, Reutens AT, et al. Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol 2012;23:123-30.
11. Mann JF, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21:527-35.
12. Fried LF, Emanuele N, Zhang JH, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892-903.
13. Ruiz S, Pergola PE, Zager RA, Vaziri ND. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013;83:1029-41.
14. Pergola PE, Krauth M, Huff JW, et al. Effect of bardoxolone methyl on kidney function in patients with T2D and stage 3b-4 CKD. Am J Nephrol 2011;33:469-76.
15. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.
16. de Zeeuw D, Akizawa T, Agarwal R, et al. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol 2013;37:212-22.
17. Lambers Heerspink HJ, Chertow GM, Akizawa T, et al. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant 2013;28:2841-50.
18. Zoja C, Corna D, Nava V, et al. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am J Physiol Renal Physiol 2013;304:F808-F819.
19. Chin M, Lee CY, Chuang JC, et al. Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of type 2 diabetes and obesity. Am J Physiol Renal Physiol 2013;304:F1438-F1446.
20. Saha PK, Reddy VT, Konopleva M, Andreeff M, Chan L. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice. J Biol Chem 2010;285:40581-92.
21. Reisman SA, Chertow GM, Hebbar S, Vaziri ND, Ward KW, Meyer CJ. Bardoxolone methyl decreases megalin and activates Nrf2 in the kidney. J Am Soc Nephrol 2012;23:1663-73.
22. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.